- Home
- IBRX vs CC Comparison
IBRX vs CC Comparison
Compare IBRX & CC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IBRX
- CC
- Stock Information
- Founded
- IBRX 2014
- CC 2014
- Country
- IBRX United States
- CC United States
- Employees
- IBRX N/A
- CC N/A
- Industry
- IBRX Biotechnology: Biological Products (No Diagnostic Substances)
- CC Major Chemicals
- Sector
- IBRX Health Care
- CC Industrials
- Exchange
- IBRX Nasdaq
- CC Nasdaq
- Market Cap
- IBRX 2.4B
- CC 1.8B
- IPO Year
- IBRX N/A
- CC N/A
- Fundamental
- Price
- IBRX $2.08
- CC $11.16
- Analyst Decision
- IBRX Strong Buy
- CC Buy
- Analyst Count
- IBRX 5
- CC 9
- Target Price
- IBRX $11.35
- CC $19.56
- AVG Volume (30 Days)
- IBRX 8.8M
- CC 2.7M
- Earning Date
- IBRX 05-16-2025
- CC 05-06-2025
- Dividend Yield
- IBRX N/A
- CC 7.45%
- EPS Growth
- IBRX N/A
- CC N/A
- EPS
- IBRX N/A
- CC 0.18
- Revenue
- IBRX $14,745,000.00
- CC $5,788,000,000.00
- Revenue This Year
- IBRX $579.28
- CC $4.64
- Revenue Next Year
- IBRX $179.96
- CC $3.95
- P/E Ratio
- IBRX N/A
- CC $62.31
- Revenue Growth
- IBRX 2270.58
- CC N/A
- 52 Week Low
- IBRX $1.83
- CC $9.33
- 52 Week High
- IBRX $9.16
- CC $29.21
- Technical
- Relative Strength Index (RSI)
- IBRX 36.89
- CC 41.86
- Support Level
- IBRX $1.83
- CC $10.32
- Resistance Level
- IBRX $2.17
- CC $12.71
- Average True Range (ATR)
- IBRX 0.18
- CC 0.56
- MACD
- IBRX -0.05
- CC 0.01
- Stochastic Oscillator
- IBRX 23.56
- CC 38.98
About IBRX ImmunityBio Inc.
ImmunityBio Inc is an integrated clinical-stage biotechnology company discovering, developing, and commercializing next-generation immuno- and cellular therapies that bolster the natural immune system to drive and sustain an immune response. Its platforms for the development of biologic product candidates include (i) antibody-cytokine fusion proteins, (ii) DNA, RNA, and recombinant protein vaccines, and (iii) cell therapies. Its focus includes bladder, lung, and colorectal cancers and GBM and its product candidate Anktiva is an IL-15 superagonist antibody-cytokine fusion protein. It has two geographical segments: the United States and Europe. Key revenue is generated from the United States.
About CC Chemours Company (The)
The Chemours Co is a provider of chemicals. It delivers customized solutions with a wide range of industrial and specialty chemicals products for various markets including coatings, plastics, refrigeration, air conditioning, etc. The company's operating segments include Titanium Technologies, Thermal & Specialized Solutions, and Advanced Performance Materials. It generates maximum revenue from the Titanium Technologies segment. The Titanium Technologies segment is a producer of TiO2 pigment, a premium white pigment used to deliver whiteness, brightness, opacity, durability, efficiency, and protection across a variety of applications. Geographically, the company derives a majority of its revenue from North America.